The Reviews Are in:
Blockbuster drug known as PARP = A future of hope
"I believe that in the next two to three years, PARP inhibitors will do for triple-negative breast cancer what trastuzumab [Herceptin] did for HER2 breast cancer." Jenny Chang, Baylor
"This development may have the potential to change patient survival . . . and appears to potentially change the natural history of at least a subclass of metastatic breast cancer [TNBC]" Clifford Hudis, MSK
“When you go home, be excited. Be really excited about this. Tell your patients there is reason to be hopeful.” Eric Winer, Dana Farber
Until now, the treatment for triple negative breast cancer has been limited. The options for metastatic patients were few and far between. Until now. The first completed studies of PARP, have shown that not only does it slow progression of disease, but patients are experiencing a complete response to the drug.
The side effects of PARP are generally well tolerated and do not include hair loss.
Where once there was no hope, no magic drug for triple negative patients, PARP is proving itself to be, as Dr. Jenny Chang, of the Baylor School of Medicine said, “What Herceptin did for HER2 breast cancer.”
“Many experts have argued that it is not possible to change survival in stage IV breast cancer. Certainly now there evidence for an alternative viewpoint; that with the use of very effective drugs, we can change overall survival, and we should aim for that." Clifford Hudis, MSK
For more information, speak to your oncologist. For information on recruiting trials for PARP click the following links:
Chang C. Interview with Neil Love. in Conversations with Oncology Investigators - Bridging the Gap between Research and Patient Care. Breast Cancer Update 2009;8(6):3-6 [Track 5; with audio].
Hudis C. Interview by L Scott Zoeller 2009 Oct 21. Extended Survival With PARP Inhibitors Changes Expectations in Metastatic Breast Cancer. Viewpoints. In OncologySTAT 2009.
Carlson R. PARP Inhibitors Show Promise Against Metastatic Triple-Negative Breast Cancer in Early Studies. Oncol Times 2009;31(15):10-11.